- Home
- VOR vs RIGL Comparison
VOR vs RIGL Comparison
Compare VOR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | RIGL |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.4M | 564.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VOR | RIGL |
|---|---|---|
| Price | $13.93 | $29.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $45.33 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.1M | 313.7K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $1.48 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $0.13 | $16.88 |
| 52 Week High | $49.95 | $52.24 |
Technical Indicators
Market Signals| Indicator | VOR | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 46.01 |
| Support Level | $11.74 | $28.08 |
| Resistance Level | $16.87 | $30.59 |
| Average True Range (ATR) | 1.00 | 1.13 |
| MACD | -0.22 | -0.22 |
| Stochastic Oscillator | 5.66 | 16.16 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.